Baxter To Offer Fill/Finish Services To Moderna's COVID-19 Vaccine In US

by Vandana Singh, Benzinga Editor

March 8, 2021 10:20 AM | 1 min read | Make a Comment

Baxter International Inc (NYSE: BAX) has agreed to provide manufacturing services for Moderna Inc's (NASDAQ: MRNA) COVID-19 Vaccine.
The agreement includes fill/finish sterile manufacturing services and supply packaging for approximately 60-90 million doses of the Moderna COVID-19 Vaccine in 2021.
Manufacturing facilities located in Bloomington, Indiana, will be used. It employs more than 700 individuals on its 600,000 square-foot campuses.
Additional details of the agreement were not disclosed.
Price Action: MRNA shares are trading lower at 1.54% at $130.24 on the last check Monday. BAX shares are up 0.37% at $78.35.

Posted In: Biotech News Health Care Contracts General COVID-19 Vaccine

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.